HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dravet syndrome — Clinical Guidelines

Overview

Dravet syndrome is a severe form of childhood epilepsy characterized by prolonged, frequent, and varied seizure types, often resistant to conventional antiepileptic drugs, leading to significant developmental delays 1 2.

Diagnosis

Clinical presentation with onset in infancy, prolonged febrile and afebrile seizures 1 2.

Absence of focal neurological deficits initially, but progressive developmental delays 1 2.

Genetic testing for SCN1A mutations often confirms diagnosis 1 2.

EEG showing characteristic slowing and multifocal epileptiform discharges 1 2.

Management

First-line adjunctive treatments: Stiripentol 50 mg/kg/day, fenfluramine 0.7 mg/kg/day, and cannabidiol show similar efficacy in reducing convulsive seizure frequency 1 2.

Efficacy outcomes: Stiripentol and fenfluramine demonstrate comparable effectiveness in achieving ≥50% and ≥75% reduction in monthly convulsive seizure frequency 1.

Seizure freedom: Fenfluramine shows a significantly greater proportion achieving 100% reduction in seizure frequency compared to placebo 4.

Safety considerations: Monitor for serious adverse events (SAEs) and discontinuation due to adverse effects, particularly with fenfluramine 1 3.

Special Populations

Pediatrics: Most treatments are evaluated in pediatric populations, with careful monitoring of developmental impact 1 2 4.

Comorbidities: Management should consider comorbidities like developmental delays and behavioral issues, though specific treatment adjustments are not detailed in the abstracts 1 2.

Key Recommendations

Initiate adjunctive therapy with stiripentol 50 mg/kg/day, fenfluramine 0.7 mg/kg/day, or cannabidiol for patients with Dravet syndrome experiencing frequent seizures (Evidence: Strong 1 2).

Fenfluramine may offer a higher likelihood of achieving seizure freedom, warranting consideration based on individual patient response and tolerance (Evidence: Strong 4).

Closely monitor for serious adverse events and adverse effects, particularly with fenfluramine, to guide treatment continuation (Evidence: Moderate 1 3).

References

1 Guerrini R, Chiron C, Vandame D, Linley W, Toward T. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 2024. link 2 Lattanzi S, Trinka E, Russo E, Del Giovane C, Matricardi S, Meletti S et al.. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Drugs 2023. link 3 Wijnen B, Witlox W, Wolff R, Fayter D, Ramaekers B, Otten T et al.. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2023. link 4 Zhang L, Li W, Wang C. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis. Acta neurologica Scandinavica 2021. link

Dravet syndrome